Table 1. Antimicrobial susceptibility testing in post-PCV10/13 period*.
| Antimicrobial agent | No. (%) of isolates | ||
|---|---|---|---|
| Susceptible | Intermediate | Resistant | |
| Penicillin (oral)† | 6 (2.2) | 75 (28.1) | 186 (69.7) |
| Penicillin (non-meningitis)‡ | 206 (77.2) | 43 (16.1) | 18 (6.7) |
| Cefotaxime (non-meningitis) | 193 (72.3) | 62 (23.2) | 12 (4.5) |
| Erythromycin | 12 (4.5) | 1 (0.4) | 254 (95.1) |
| Clindamycin | 62 (23.2) | 2 (0.7) | 203 (76) |
| Tetracycline | 25 (9.4) | - | 242 (90.6) |
| Chloramphenicol | 195 (73.0) | - | 72 (27.0) |
| TMP/SMX | 92 (34.5) | 44 (16.5) | 131 (49.1) |
| Levofloxacin | 266 (99.6) | - | 1 (0.4) |
PCV = pneumococcal conjugate vaccine, TMP/SMX = trimethoprim/sulfamethoxazole, CLSI = Clinical & Laboratory Standards Institute, MIC = minimal inhibitory concentration.
*Susceptibility criteria of 2014 CLSI guideline were employed; †Breakpoints of MIC ≤ 0.06 were employed for the classification of susceptibility; ‡Breakpoints of MIC ≤ 2 were employed for the classification of susceptibility.